Home›Doctors›Zafer Gülbaş
Zafer Gülbaş
Profile listed by XCuro

Dr. Zafer Gülbaş

Prof. Dr. · Hematology & Oncology · Bone Marrow Transplant
Anadolu Medical Center xcuro partner English, Turkish
Accreditations
International Organization for StandardizationJCI

About Prof. Dr. Zafer Gülbaş

Prof. Dr. Zafer Gülbaş is a hematologic oncology specialist at Anadolu Medical Center Hospital in Gebze, near Istanbul. According to the hospital, he has worked there since 2014 as a hematologic oncology specialist and director of the Bone Marrow Transplant Center.

Clinical Focus

The hospital lists lymphomas and myeloma as his specialties, within the Hematology, Hematologic Oncology and Bone Marrow Transplant departments.

Experience

According to the hospital, his education and training include Hacettepe University Medical School, Anadolu University Medical School, Atatürk Pulmonary Diseases and Thoracic Surgery Center, Hadassah Medical Center (Israel), Fred Hutchinson Cancer Research Center (Seattle), MD Anderson Cancer Center and Princess Margaret Hospital, University of Toronto.

Facts you can check

Procedures performed

Specialties

Education & training

  • Degree
    Hacettepe University School of Medicine
    MD · Medicine
  • Degree
    Anadolu University School of Medicine
    MD · Medicine

Professional memberships

  • Membership
    European Hematology Association (EHA)
  • Membership
    American Society of Hematology (ASH)
  • Membership
    European Society for Medical Oncology (ESMO)

Membership reflects participation in a professional body — not an endorsement of this doctor by that organization.

Getting to Turkey from the U.S.

Visa. U.S. passport holders travel to Turkey without a visa for tourism or short business, for up to 90 days within any 180-day period.

Flights. Turkish Airlines flies nonstop to Istanbul from New York, Newark, Boston, Washington, Atlanta, Miami, Chicago, Dallas, Houston, Seattle, San Francisco and Los Angeles. East-coast flights run about 10 hours, west-coast about 13. Istanbul is 7 hours ahead of New York in summer and 8 hours in winter, because Turkey stays on UTC+3 all year.

U.S. State Department advisory. Level 2 – Exercise Increased Caution (reissued June 9, 2026). The advisory says not to travel within 10 km of the borders with Syria or Iraq; Istanbul is far from both.Read the advisory.

How xcuro works

  • Free for you

    You don't pay xcuro anything. If you go ahead with treatment at an xcuro partner clinic, that clinic pays us a referral fee.

  • Rankings aren't for sale

    Clinics can't pay to be listed, to appear higher or to change their reviews.

  • Ratings you can check

    Clinic ratings come from Google and Trustpilot, and each one links to its source.

  • Prices with sources

    Every U.S. price we compare against names its source. Your own quote comes from the clinic in writing.

Frequently asked questions about Dr. Zafer Gülbaş

Where does Dr. Zafer Gülbaş practice?

Dr. Zafer Gülbaş works at Anadolu Medical Center in Istanbul, Turkey.

What are Dr. Zafer Gülbaş's qualifications?

Dr. Zafer Gülbaş has trained at Hacettepe University School of Medicine and Anadolu University School of Medicine, credentials and memberships include European Hematology Association (EHA); American Society of Hematology (ASH); European Society for Medical Oncology (ESMO). Details and sources are listed on this page.

What procedures does Dr. Zafer Gülbaş perform?

Bone Marrow Transplant, Stem Cell Therapy.

Does Dr. Zafer Gülbaş speak English?

Yes. Dr. Zafer Gülbaş speaks English, Turkish.

How do I get to Dr. Zafer Gülbaş's clinic from the U.S.?

U.S. passport holders travel to Turkey without a visa for tourism or short business, for up to 90 days within any 180-day period. Turkish Airlines flies nonstop to Istanbul from New York, Newark, Boston, Washington, Atlanta, Miami, Chicago, Dallas, Houston, Seattle, San Francisco and Los Angeles. East-coast flights run about 10 hours, west-coast about 13. Istanbul is 7 hours ahead of New York in summer and 8 hours in winter, because Turkey stays on UTC+3 all year.

What happens after you send a request

  1. You send a request through the form — this does not commit you to treatment.
  2. An XCuro coordinator contacts you to understand what you are looking for.
  3. You share the relevant medical details and photos for the clinic to review.
  4. The clinic's medical team assesses suitability and prepares a proposal.
  5. If you decide to go ahead, you plan the appointment and travel together.

Whether a procedure is suitable for you — and the technique, risks and likely results — can only be confirmed by an individual medical assessment.

About the clinic

Anadolu Medical Center xcuro partner
Istanbul · Turkey
★ 4.0

Hospital in Gebze near Istanbul, established in 2005 and partnered with Johns Hopkins Medicine; it reports 201 beds, 159 physicians and more than 3,000 bone marrow transplants since 2010.

View clinic profile

Research & evidence

12 peer-reviewed sources

Peer-reviewed studies relevant to the procedures Zafer Gülbaş performs. Compiled from systematic reviews, meta-analyses and clinical research indexed on PubMed.

  1. Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.
    Rasche L, et al. · Bone Marrow Transplantation · 2026
  2. Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.
    Li Q, et al. · Therapeutic Advances in Hematology · 2026
    Meta-analysisPMID 41492445DOI
  3. Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.
    Li X, et al. · Annals of Hematology · 2026
    Meta-analysisPMID 42053782DOI
  4. Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis.
    Shawabkeh AE, et al. · Frontiers in Oncology · 2026
    Meta-analysisPMID 41948499DOI
  5. Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression.
    Lee ARYB, et al. · Transplantation and Cellular Therapy · 2026
    Meta-analysisPMID 42264269DOI

Compiled from peer-reviewed medical literature indexed on PubMed. This overview is for general education and is not medical advice.